A Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of RX 3341 Compared With Tigecycline for the Treatment of Complicated Skin and Skin Structure Infections.

Trial Profile

A Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of RX 3341 Compared With Tigecycline for the Treatment of Complicated Skin and Skin Structure Infections.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2013

At a glance

  • Drugs Delafloxacin (Primary) ; Tigecycline
  • Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Melinta Therapeutics
  • Most Recent Events

    • 18 May 2009 Results have been presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases.
    • 26 Jan 2009 Final results are reported in a Rib-X Pharmaceuticals media release.
    • 08 Dec 2008 Top-line results reported in a Rib-X Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top